Close Menu

NEW YORK – Nestlé Health Science subsidiary ProciseDx said today that it has received CE marking for a point-of-care instrument platform.

ProciseDx said it is developing a broad portfolio of rapid point-of-care tests for use with the instrument in physician offices, retail clinics, and urgent care settings. The San Diego, California-based firm is developing diagnostic and treatment monitoring tests to quantify markers for inflammatory and auto-immune diseases, such as celiac disease, and metabolic syndromes, such as diabetes and pre-diabetes.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.